|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.730 USD | +6.46% |
|
-6.61% | -13.56% |
| 06-15 | Waldencast plc Announces Fda Approval of Obagi Saypha Chiq Injectable Hyaluronic Acid Gel | CI |
| 06-15 | Waldencast Says US FDA Approves Obagi Saypha ChIQ Injectable Hyaluronic Acid Gel | MT |
| Market Cap | 202M 176M 163M 150M 283M 19.3B 288M 1.93B 756M 9.59B 759M 743M 32.24B | P/E 2026 * |
-2.44x | P/E 2027 * | -2.61x |
|---|---|---|---|---|---|
| Enterprise Value | 311M 270M 251M 231M 435M 29.65B 443M 2.97B 1.16B 14.73B 1.17B 1.14B 49.52B | EV / Sales 2026 * |
1.09x | EV / Sales 2027 * | 0.98x |
| Free-Float |
46.06% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +6.46% | ||
| 1 week | -6.61% | ||
| Current month | -7.67% | ||
| 1 month | -7.67% | ||
| 3 months | +82.58% | ||
| 6 months | -10.22% | ||
| Current year | -13.56% |
| 1 week | 1.59 |  | 1.74 |
| 1 month | 1.59 | | 1.86 |
| Current year | 0.72 | | 2.01 |
| 1 year | 0.72 | | 3.22 |
| 3 years | 0.72 | | 12 |
| 5 years | 0.72 | | 12.1 |
| 10 years | 0.72 | | 12.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 2026-07-29 | |
Elisabeth Milan
LAW | General Counsel | - | 2023-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 60 | 2020-12-31 | |
Aaron Chatterley
BRD | Director/Board Member | 60 | 2021-11-30 |
Juliette Hickman
BRD | Director/Board Member | 52 | 2021-02-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.46% | -6.61% | -18.75% | -70.18% | 202M | |
| +0.89% | +1.03% | +40.06% | +51.91% | 35.62B | |
| -1.71% | +7.08% | -1.16% | +14.44% | 22.21B | |
| -0.21% | +1.39% | +2.26% | - | 10.82B | |
| -0.25% | +0.03% | -31.27% | -46.29% | 4.02B | |
| -4.16% | +1.38% | -42.85% | - | 3.83B | |
| +0.81% | +0.92% | +66.99% | - | 1.52B | |
| +0.31% | +3.45% | -22.67% | - | 1B | |
| +0.57% | 0.00% | - | - | 497M | |
| -1.75% | -3.56% | -20.72% | +142.05% | 409M | |
| Average | +0.05% | -0.86% | -3.12% | +18.39% | 8.01B | |
| Weighted average by Cap. | -0.28% | +1.05% | +15.10% | +32.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 286M 248M 231M 213M 401M 27.29B 408M 2.73B 1.07B 13.56B 1.07B 1.05B 45.59B | 315M 273M 254M 234M 441M 30.05B 449M 3.01B 1.18B 14.93B 1.18B 1.16B 50.19B |
| Net income | -81.16M -70.49M -65.46M -60.37M -114M -7.75B -116M -775M -303M -3.85B -305M -298M -12.94B | -76.15M -66.14M -61.42M -56.64M -107M -7.27B -109M -727M -285M -3.61B -286M -280M -12.14B |
| Net Debt | 108M 94.16M 87.44M 80.64M 152M 10.35B 155M 1.04B 405M 5.14B 407M 398M 17.28B | 107M 93.2M 86.55M 79.82M 150M 10.24B 153M 1.02B 401M 5.09B 403M 394M 17.11B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-28 | US$1.625 | -2.69% | 451,652 |
| 26-07-30 | US$1.710 | +5.23% | 607,435 |
| 26-07-29 | US$1.625 | -2.69% | 451,652 |
| 26-07-28 | US$1.670 | -2.91% | 248,224 |
| 26-07-27 | US$1.720 | +1.78% | 433,308 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- WALD Stock
Select your edition
All financial news and data tailored to specific country editions
